Novavax (NVAX) | Financial Analysis & Statements
Novavax Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
147.1M
Gross Profit
125.0M
84.98%
Operating Income
15.0M
10.22%
Net Income
17.5M
11.91%
EPS (Diluted)
$0.11
Balance Sheet Metrics
Total Assets
1.2B
Total Liabilities
1.3B
Shareholders Equity
-127.8M
Cash Flow Metrics
Operating Cash Flow
-41.8M
Free Cash Flow
-41.7M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Novavax Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 682.2M | 556.4M | 1.6B | 197.6M |
| Cost of Goods Sold | 73.0M | 202.7M | 343.8M | 902.6M | 0 |
| Gross Profit | 1.1B | 479.4M | 212.6M | 696.3M | 197.6M |
| Gross Margin % | 93.5% | 70.3% | 38.2% | 43.5% | 100.0% |
| Operating Expenses | |||||
| Research & Development | 342.3M | 391.2M | 737.5M | 1.2B | 2.5B |
| Selling, General & Administrative | 157.5M | 337.2M | 468.9M | 488.7M | 298.4M |
| Other Operating Expenses | - | - | -427.3M | -382.9M | -948.7M |
| Total Operating Expenses | 499.8M | 728.4M | 779.1M | 1.3B | 1.9B |
| Operating Income | 550.6M | -248.9M | -566.5M | -644.7M | -1.7B |
| Operating Margin % | 49.0% | -36.5% | -101.8% | -40.3% | -853.6% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 22.5M | 20.1M | 14.4M | 19.9M | 21.1M |
| Other Non-Operating Income | -85.9M | 92.4M | 37.9M | 11.0M | -6.8M |
| Pre-tax Income | 442.2M | -176.6M | -543.0M | -653.6M | -1.7B |
| Income Tax | 1.9M | 10.9M | 2.0M | 4.3M | 29.2M |
| Effective Tax Rate % | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | 440.3M | -187.5M | -545.1M | -657.9M | -1.7B |
| Net Margin % | 39.2% | -27.5% | -98.0% | -41.1% | -882.5% |
| Key Metrics | |||||
| EBITDA | 618.9M | -160.0M | -487.4M | -604.7M | -1.7B |
| EPS (Basic) | $2.72 | $-1.23 | $-5.41 | $-8.42 | $-23.44 |
| EPS (Diluted) | $2.58 | $-1.23 | $-5.41 | $-8.42 | $-23.44 |
| Basic Shares Outstanding | 161991000 | 152190000 | 100768000 | 78183000 | 74400000 |
| Diluted Shares Outstanding | 161991000 | 152190000 | 100768000 | 78183000 | 74400000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Novavax Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 240.6M | 530.2M | 568.5M | 1.3B | 1.5B |
| Short-term Investments | 494.4M | 392.9M | - | - | 0 |
| Accounts Receivable | 106.4M | 108.3M | 297.2M | 82.4M | 455.0M |
| Inventory | 11.5M | 8.7M | 41.7M | 36.7M | 8.9M |
| Other Current Assets | 9.9M | 21.9M | 155.7M | 76.4M | 44.6M |
| Total Current Assets | 978.3M | 1.1B | 1.1B | 1.7B | 2.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 22.9M | 161.6M | 185.2M | 106.2M | 40.1M |
| Goodwill | 226.9M | 215.0M | 254.9M | 252.7M | 263.0M |
| Intangible Assets | - | - | - | - | 4.8M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 17.1M | 24.0M | 35.2M | 28.5M | 24.3M |
| Total Non-Current Assets | 198.2M | 431.5M | 653.6M | 555.3M | 421.6M |
| Total Assets | 1.2B | 1.6B | 1.8B | 2.3B | 2.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 24.6M | 41.6M | 132.6M | 216.5M | 127.0M |
| Short-term Debt | 2.5M | 7.0M | 5.1M | 352.1M | 130.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 185.6M | 219.6M | 861.4M | 930.1M | 36.1M |
| Total Current Liabilities | 460.0M | 1.2B | 1.6B | 2.5B | 2.4B |
| Non-Current Liabilities | |||||
| Long-term Debt | 246.3M | 223.4M | 223.9M | 197.7M | 323.5M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 239.1M | 359.6M | 33.1M | 55.7M | 42.1M |
| Total Non-Current Liabilities | 844.3M | 1.0B | 879.3M | 432.8M | 538.1M |
| Total Liabilities | 1.3B | 2.2B | 2.5B | 2.9B | 2.9B |
| Equity | |||||
| Common Stock | 1.6M | 1.6M | 1.4M | 868.0K | 764.0K |
| Retained Earnings | -4.6B | -5.0B | -4.8B | -4.3B | -3.6B |
| Treasury Stock | 103.0M | 95.9M | 92.3M | 90.7M | 85.1M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -127.8M | -623.8M | -716.9M | -634.1M | -351.7M |
| Key Metrics | |||||
| Total Debt | 248.8M | 230.4M | 229.1M | 549.8M | 454.0M |
| Working Capital | 518.3M | -25.5M | -491.2M | -756.6M | -235.2M |
Balance Sheet Composition
Novavax Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 440.3M | -187.5M | -545.1M | -657.9M | -1.7B |
| Depreciation & Amortization | 27.6M | 48.5M | 41.2M | 29.1M | 12.7M |
| Stock-Based Compensation | 36.0M | 48.2M | 85.4M | 130.3M | 183.6M |
| Working Capital Changes | -887.7M | 48.5M | -376.8M | -361.2M | 1.7B |
| Operating Cash Flow | -378.0M | -60.4M | -796.2M | -863.5M | 322.9M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | - | - | - | 0 | 0 |
| Investment Purchases | -445.3M | -825.6M | 0 | 0 | -2.2M |
| Investment Sales | 353.7M | 443.6M | 0 | 0 | 159.8M |
| Investing Cash Flow | -71.9M | -189.4M | 0 | 0 | 157.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 42.6M | 0 | 0 | 175.2M | 0 |
| Debt Repayment | -10.1M | -4.0M | -352.3M | -93.6M | -127.9M |
| Financing Cash Flow | 32.5M | 259.3M | 4.3M | 325.6M | 437.0M |
| Free Cash Flow | -251.0M | -101.9M | -772.8M | -508.9M | 265.5M |
| Net Change in Cash | -417.4M | 9.5M | -791.9M | -537.9M | 917.5M |
Cash Flow Trend
Novavax Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
3.28
Forward P/E
-8.33
Price to Book
-10.37
Price to Sales
1.23
PEG Ratio
-0.03
Profitability Ratios
Profit Margin
39.19%
Operating Margin
14.23%
Return on Equity
-344.65%
Return on Assets
25.72%
Financial Health
Current Ratio
2.13
Debt to Equity
-2.18
Beta
2.65
Per Share Data
EPS (TTM)
$2.58
Book Value per Share
$-0.79
Revenue per Share
$6.94
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| NVAX | 1.3B | 3.28 | -10.37 | -344.65% | 39.19% | -2.18 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






